BI
Boehringer Ingelheim Venture Fund
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Sep 18, 2026
Boehringer Ingelheim Venture Fund is a corporate venture investment operation identified in Cloverleaf Bio and Brainomix financing histories.
Recorded funding activity
Cloverleaf develops engineered transfer-RNA therapies intended to inhibit cancer cells’ RNA-modifying enzymes. Brainomix develops AI imaging tools for stroke and lung fibrosis. The announcements connect the venture operation to both experimental therapeutics and clinical image analysis.
- Rounds participated in
- 0
- Confirmed lead rounds
- — All roles disclosed
- New companies
- 0 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share
By stage
No activity in this selection.
By primary sector
No activity in this selection.
By country
No activity in this selection.
Rounds
0 in this selectionNo rounds match this selection.